Spots Global Cancer Trial Database for primary mediastinal lymphoma
Every month we try and update this database with for primary mediastinal lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | NCT03019666 | Multiple Myelom... Non-Hodgkin Lym... Diffuse Large B... Mantle-Cell Lym... Follicular Lymp... Indolent B Cell... Primary Mediast... Lymphoplasmacyt... | Nicotinamide Ex... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | NCT03019666 | Multiple Myelom... Non-Hodgkin Lym... Diffuse Large B... Mantle-Cell Lym... Follicular Lymp... Indolent B Cell... Primary Mediast... Lymphoplasmacyt... | Nicotinamide Ex... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients | NCT03028103 | Diffuse Large B... Primary Mediast... Mantle Cell Lym... Advanced Solid ... Marginal Zone L... | Tazemetostat Fluconazole Omeprazole Repaglinide | 18 Years - | Ipsen | |
| Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients | NCT03028103 | Diffuse Large B... Primary Mediast... Mantle Cell Lym... Advanced Solid ... Marginal Zone L... | Tazemetostat Fluconazole Omeprazole Repaglinide | 18 Years - | Ipsen | |
| Radiotherapy in Primary Mediastinal Lymphoma | NCT01230008 | Adjuvant Radiot... | no drugs | 18 Years - 65 Years | Instituto Mexicano del Seguro Social | |
| Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors | NCT03010982 | Diffuse Large B... Primary Mediast... Mantle-Cell Lym... Follicular Lymp... Marginal Zone L... Advanced Solid ... | Tazemetostat an... | 18 Years - | Ipsen | |
| Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL | NCT06188676 | Primary Mediast... | Cyclophosphamid... Doxorubicin Hyd... Etoposide Phosp... Prednisolone Rituximab Vincristine Sul... Filgrastim Pegfilgrastim Nivolumab 40 mg... | 18 Years - 70 Years | National Research Center for Hematology, Russia |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
